title: Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment.
abstract: OBJECTIVE
  Cancer pain is the most serious symptom for patients, especially during their terminal phase, when palliative medicine is needed. Our study tried to verify the usefulness of single-shot intravenous administration of Samarium (Sm)-153EDTMP in patients with bone metastases (group-A, N=53, males=25, females=28, age range: 30-69 years), as well as to compare a series of variables, using as a control group (group-B, N=37, males=17, females=20, age range: 30-69 years) with patients who were under drug treatment given from a physician specialized in palliative medicine.
  
  
  METHODS
  Both groups answered the following questionnaires: Greek Brief Pain Inventory (GBPI), Brief Multidimensional Life Satisfaction Scale (BMLSS), Hospital Anxiety Depression Scale (HADS) and ECOG performance status.
  
  
  RESULTS
  Pain severity and pain interference improvement p=0.0005 for both groups. HADS-anxiety: Samarium group, p= 0.397, drugs group p= 0.031. HADS-depression improvement for both groups p=0.031 and p=0.003, respectively. BMLSS improvement p=0.029 and p=0.265, while EGOG PS improvement was p=0.005 and p=0.014, respectively (numeric values).
  
  
  CONCLUSIONS
  Intravenous administration of Sm-153EDTMP was equivalent to drug treatment against cancer pain for patients with multiple bone metastasis, an option for those patients who are intolerant or resistant to drug treatment. Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result.
authors.affiliation: Nuclear Medicine Department, Anticancer Hospital "Agios Savvas", Athens, Greece.
authors.forename: Gregory
authors.initials: G
authors.lastname: Tsoucalas
authors.forename: Eleni
authors.initials: E
authors.lastname: Sarafianou
authors.forename: Antonios
authors.initials: A
authors.lastname: Galanos
authors.forename: Efi
authors.initials: E
authors.lastname: Parpa
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Baziotis
authors.forename: Markos
authors.initials: M
authors.lastname: Sgantzos
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Gennimata
authors.forename: Maria
authors.initials: M
authors.lastname: Lymperi
authors.forename: Elisavet
authors.initials: E
authors.lastname: Patiraki
authors.forename: Vasilios
authors.initials: V
authors.lastname: Kouloulias
authors.forename: Kyriaki
authors.initials: K
authors.lastname: Mystakidou
mesh_terms: D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary*; D005260:Female; D006115:Greece; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D004364:Pharmaceutical Preparations; D012493:Samarium / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D004364:Pharmaceutical Preparations; D012493:Samarium; C061972:samarium Sm-153 lexidronam